Modulated electro-hyperthermia in stage III and IV pancreatic cancer:Results of an observational study on 158 patients

作     者：Giammaria Fiorentini Donatella Sarti Girolamo Ranieri Cosmo Damiano Gadaleta Caterina Fiorentini Carlo Milandri Andrea Mambrini Stefano Guadagni 

作者机构：Department of Onco-HematologyAzienda Ospedaliera“Ospedali Riuniti Marche Nord”Pesaro 61122Italy Oncology DepartmentOspedale S.Maria Della MisericordiaASUR1Urbino 61029Italy Interventional and Integrated Medical OncologyNational Cancer Research CentreIRCCS Istituto Tumori"Giovanni Paolo II"Bari 70124Italy Department of Medical BiothecnologiesDivision of CardiologyUniversity Hospital of SienaSiena 53100Italy Medical Oncology UnitSan Donato HospitalArezzo 52100Italy Department of Oncology-ASL Toscana Nord OvestMassa Carrara HospitalMassa 54100Italy Applied Clinical Sciences and BiotechnologySection of General SurgeryUniversity of L’AquilaL’Aquila 67100Italy 

出 版 物：《World Journal of Clinical Oncology》 (世界临床肿瘤学杂志（英文版）)

年 卷 期：2021年第12卷第11期

页      面：1064-1071页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：the Istituto Tumori Giovanni Paolo II Bari Italy Institutional Review Board(Approval No.948/CE) 

主　　题：Modulated electro-hyperthermia Locally advanced pancreatic cancer Tumor response Survival 

摘      要：BACKGROUND An increasing number of studies report the beneficial effects of regional hyperthermia in association with chemotherapy(CHT)and radiotherapy for the treatment of pancreatic cancer;in particular,the use of modulated electrohyperthermia(mEHT)results in increased survival and tumor *** To compare outcomes of CHT alone or in association with mEHT for the treatment of stage III and IV pancreatic *** This was an observational retrospective study;data were collected for patients with stage III-IV pancreatic cancer that were treated with CHT alone or in combination with mEHT from 2003 to 2019.A total of 158 patients were included in the study out 270 patients screened in four Italian hospitals;58(37%)of these received CHT+mEHT and 100(63%)*** was mainly gemcitabine-based regimens in both *** Overall(19.5 mo vs 11.02 mo,P0.001)and progression-free(12 mo vs 3 mo,P0.001)survival were better for the CHT+mEHT group compared to the CHT *** association of mEHT resulted also in an improvement of tumor response with disease control rate 95%vs 58%(P0.001)at 3 *** was comparable in the two study groups,and mEHT related adverse events were limited in 8 patients presenting G1-2 skin *** The addition of mEHT to systemic CHT improved overall and progression-free survival and local tumor control with comparable toxicity.